Business Context and Reporting Period
Company: enVVeno Medical Corp (NVNO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A late clinical-stage medical device company developing bioprosthetic solutions for deep venous disease. The lead product, VenoValve (surgical), is in post-enrollment follow-up of its U.S. pivotal study. The second product, enVVe (non-surgical), is in pre-clinical testing. The company operates in a single segment and is headquartered in Irvine, California.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(4,539) | $(5,642) | $(15,736) | $(15,590) |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.35) | $(0.78) | $(0.97) |
| Operating Expenses | $4,883 | $6,170 | $16,886 | $17,127 |
| Cash & Cash Equivalents (End of Period) | $1,544 | $17,915 | $1,544 | $17,915 |
| Short-term Investments | $29,408 | $41,399 | $29,408 | $41,399 |
| Total Cash & Investments | $30,952 | $59,314 | $30,952 | $59,314 |
| Working Capital | $29,099 | $41,639 | $29,099 | $41,639 |
| Net Cash Used in Operating Activities (9M) | $(12,125) | $(11,733) | $(12,125) | $(11,733) |
Note: The company has no debt obligations listed on the balance sheet. Total liabilities consist primarily of operating lease liabilities ($791k) and accounts payable/accrued expenses ($2,114k).
Material Changes vs. Prior Period
- Net Loss Improvement (Q3): Net loss decreased by $1.1 million (20%) compared to Q3 2024, driven by a $1.3 million reduction in operating expenses, partially offset by lower investment income.
- Expense Reduction:
- R&D: Decreased $0.3 million (10%) in Q3 2025 due to lower pivotal study follow-up costs.
- SG&A: Decreased $1.0 million (31%) in Q3 2025, attributed to non-recurring legal costs in the prior year, lower stock-based compensation, and a $0.3 million recovery of a reserve for uncollectible prepaid clinical costs.
- Cash Position: Total cash and investments declined from $43.2 million at year-end 2024 to $31.0 million as of September 30, 2025. The burn rate is approximately $4 million per quarter.
- Equity Activity: During the nine months ended September 30, 2025, the company issued 2.68 million shares via warrant exercises, raising $241,000. No public offerings occurred in 2025.
Guidance, Outlook, Risks, and Unusual Items
Regulatory Status (VenoValve)
- Not-Approvable Letter: On August 19, 2025, the FDA issued a not-approvable letter for the VenoValve PMA application. The FDA cited insufficient hemodynamic data to correlate with clinical improvement and safety concerns regarding the open surgical procedure.
- Appeal Process: The company filed a supervisory appeal on September 18, 2025. An in-person meeting with FDA leadership occurred in October 2025. A decision on the appeal is expected by the end of 2025.
- Impact on enVVe: The company is delaying the filing of the Investigational Device Exemption (IDE) for the non-surgical enVVe product until regulatory clarity is achieved regarding VenoValve. The IDE is expected to be filed in Q1 2026.
Liquidity and Capital Resources
- Burn Rate: Management anticipates the cash burn rate will increase from ~$4 million per quarter to between $5 million and $7 million per quarter as clinical activities continue.
- Runway: Management believes current capital resources ($31.0 million) are sufficient to meet obligations for at least one year from the filing date.
Nasdaq Listing Deficiency
- Notice Received: On October 7, 2025, Nasdaq notified the company that its stock price had fallen below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
- Compliance Period: The company has 180 days (until April 6, 2026) to regain compliance by maintaining a closing bid price of $1.00 or more for 10 consecutive trading days.
- Delisting Risk: Failure to comply may lead to delisting, though the company may be eligible for an additional 180-day period if it meets other listing standards and proposes a reverse stock split.
Investor Verification Checklist
- FDA Appeal Outcome: Monitor the expected end-of-2025 decision on the VenoValve supervisory appeal, which is critical for product commercialization.
- Nasdaq Compliance: Verify if the stock price sustains above $1.00 to avoid delisting proceedings by April 2026.
- Cash Burn vs. Runway: Assess the projected increase in quarterly burn rate ($5M-$7M) against the current $31M cash balance to determine the need for near-term capital raises.
- enVVe Timeline: Confirm the filing date of the enVVe IDE application, currently targeted for Q1 2026, contingent on VenoValve regulatory resolution.
- Vendor Dispute Resolution: Review the status of the $0.6 million reserve for uncollectible prepaid clinical costs and the subsequent $0.3 million recovery mentioned in SG&A.